

Design, synthesis and pharmacological evaluation of three novel dehydroabietyl piperazine dithiocarbamate ruthenium (II) polypyridyl complexes as potential antitumor agents: DNA damage, cell cycle arrest and apoptosis inducing

Hao-Ran Wang^{1,†}, Jian-Hua Wei^{1,†,*}, Hong Jiang¹, Ye Zhang^{1,2}, Cai-Na Jiang^{1,*}, Xian-Li Ma^{1,2,*}

¹ *School of Pharmacy, Guilin Medical University, Guilin 541004, China.*

² *Department of Chemistry & Pharmaceutical Science, Guilin Normal College, Xinyi Road 15, Guangxi 541001, China*

[†] These authors contributed equally to this work.

E-mail addresses: 120096545@qq.com (Xian-Li Ma), 429477986@qq.com (Cai-Na Jiang)

1. Metal accumulation in T-24 cell




Figure S1: ICP-MS of T-24 cell uptake of complexes **6a-6c**. T-24 cells incubated with complexes **6a-6c** for 2h at 37°C in a humidified atmosphere of 5% CO₂/95% air. All cells were collected, and then resuspended in 0.5 mL of PBS solution. Ruthenium concentrations were determined by ICP-MS (Inductively-Coupled Plasma Mass Spectrometry). Samples then treated with concentrated HNO₃ overnight prior to analysis. Cellular concentrations of ruthenium were reported per µg of protein.

2. Cell cycle arrest analysis




Figure S2: Cell cycle distribution of T-24 cells exposed to the **6a** and **6c** (0.5, 1, 2 μM) for 24 h. Effects on cell cycle progression of these compounds were examined according to the procedures described in the experimental section.







Figure S3: HPLC [chromatograms](#) for **6a**, **6b** and **6c** in aqueous solution (1 mg/mL) in the time courses of 0 h, 12 h and 24h, respectively. Column: reversed-phase C18 column (Agilent 5 TC-C18 250*4.6 mm.). Column temperature: 35°C. Mobile phase: CH₃OH/H₂O (30:70). Flow rate: 1.0 ml/min. Injection volume: 20 µM.


3. ^1H NMR, ^{13}C NMR and HRMS of compounds 6a-6c.




tert-butyl 4-((1R,4aS)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carbonyl)piperazine-1-carboxylate (3). Compound 1 (1 equivalent, 15 mmol) was dissolved in dichloromethane (100 mL), and excess oxalyl chloride (3.5 equivalent, 52.5 mmol) was added. After the reaction, the oxalyl chloride was removed, Boc-piperazine (1.2 equivalent, 18 mmol) was dissolved in the reaction solution, and the product 3 was obtained by separation and purification. It is a white solid with a yield of 82.3%. ^1H NMR (400 MHz, CDCl_3) δ 7.13 (d, $J = 8.2$ Hz, 1H), 6.96 (d, $J = 8.1$ Hz, 1H), 6.87 (s, 1H), 3.61 (dd, $J = 22.9, 12.5$ Hz, 4H), 3.40-3.30 (m, 4H), 2.92 (d, $J = 18.4$ Hz, 1H), 2.85 (s, 1H), 2.79 (s, 1H), 2.27 (t, $J = 11.2$ Hz, 2H), 1.75 (dd, $J = 24.8, 18.7$ Hz, 6H), 1.58 (s, 1H), 1.43 (s, 9H), 1.32 (s, 3H), 1.22 (s, 3H), 1.20 (s, 3H), 1.19 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 177.59, 155.05, 147.24, 145.71, 135.15, 127.10, 124.20, 123.81, 80.63, 53.43, 46.97, 45.40, 37.66, 37.46, 35.50, 33.45, 30.61, 28.40, 25.50. HRMS (m/z) (ESI): $\text{C}_{29}\text{H}_{44}\text{N}_2\text{O}_3$ $[\text{M}+\text{H}]^+$ calcd for: 469.3352 found: 469.3457.





S2 #2-9 RT: 0.01-0.03 AV: 8 NL: 4.82E5
T: FTMS + p ESI Full ms [450.00-650.00]





((1R,4aS)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl)(piperazin-1-yl)methanone (4). Compound 3 (1 equivalent, 15 mmol) was dissolved in dichloromethane (100 mL), and excess trifluoroacetic acid (3.5 equivalents, 52.5 mmol) was added. After the reaction, extract and adjust the pH to neutral to obtain product 4. It is a white solid with a yield of 76.5%. ^1H NMR (400 MHz, CDCl_3) δ 7.14 (d, $J = 8.2$ Hz, 1H), 6.99 (d, $J = 9.6$ Hz, 1H), 6.89 (s, 1H), 3.98 (dd, $J = 32.2, 14.9$ Hz, 4H), 3.17 (s, 4H), 2.91 (dd, $J = 50.3, 23.3$ Hz, 3H), 2.27 (t, $J = 11.6$ Hz, 2H), 1.76 (dd, $J = 22.3, 16.6$ Hz, 4H), 1.67 - 1.39 (m, 3H), 1.33 (s, 3H), 1.24 (s, 3H), 1.22 (s, 3H), 1.21 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 177.49 (s), 146.60 (s), 145.84 (s), 134.85 (s), 127.13 (s), 124.01 (d, $J = 18.7$ Hz), 46.80 (s), 45.49 (s), 43.55 (s), 42.62 (s), 37.49 (d, $J = 19.5$ Hz), 35.75 (s), 33.46 (s), 30.45 (s), 25.39 (s), 23.98 (d, $J = 2.9$ Hz), 22.16 (s), 18.66 (d, $J = 13.8$ Hz). HRMS (m/z) (ESI): $\text{C}_{24}\text{H}_{36}\text{N}_2\text{O}$ $[\text{M}+\text{H}]^+$ calcd for: 369.2828 found: 369.2919.







D:\DATA\WJH20180920\WHR\20190910\sc


09/10/19 15:47:13



sc #1 RT: 0.01 AV: 1 NL: 3.01E6
T: FTMS + p ESI Full ms [300.00-500.00]







sodium 4-((1R,4aS)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carbonyl)piperazine-1-carbodithioate (5). Compound 4 (1 equivalent, 15 mmol) was dissolved in dichloromethane (100 mL), and sodium hydroxide solution (1 equivalent, 15 mmol) and excess CS₂ were added. Separate and purify after the reaction to obtain purified product 5. It is a white solid with a yield of 63.2%. ¹H NMR (400 MHz, CDCl₃) δ 7.15 (d, *J* = 8.2 Hz, 1H), 6.99 (dd, *J* = 8.2, 1.6 Hz, 1H), 6.89 (s, 1H), 4.14 - 4.06 (m, 1H), 3.79 (dd, *J* = 18.4, 13.4 Hz, 5H), 3.04 - 2.73 (m, 3H), 2.30 (d, *J* = 11.8 Hz, 2H), 2.04 (s, 1H), 1.84-1.66 (m, 5H), 1.56 (dd, *J* = 12.7, 6.9 Hz, 1H), 1.44 (dd, *J* = 13.3, 10.4 Hz, 1H), 1.35 (s, 3H), 1.29 - 1.24 (m, 4H), 1.23 (d, *J* = 3.3 Hz, 3H), 1.21 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 177.49, 146.60, 145.84, 134.85, 127.13, 124.10, 123.91, 46.80, 45.49, 43.55, 42.62, 37.59, 37.39, 35.75, 33.46, 30.45, 25.39, 23.99, 23.96, 22.16, 18.73, 18.59. HRMS (*m/z*) (ESI): C₂₅H₃₅N₂NaOS₂ [*M*+*H*]⁺ calcd for: 489.2088, found: 489.21.











(6a). Yield 56.2%. ^1H NMR (400 MHz, DMSO) δ 9.87 (d, J = 5.3 Hz, 2H), 8.83 (d, J = 8.1 Hz, 2H), 8.50 (d, J = 8.2 Hz, 2H), 8.37 (d, J = 8.9 Hz, 2H), 8.26 (dd, J = 15.3, 7.9 Hz, 4H), 7.93 (d, J = 4.1 Hz, 2H), 7.54 – 7.48 (m, 2H), 7.13 (dd, J = 7.0, 3.8 Hz, 1H), 6.97 – 6.67 (m, 2H), 3.86 (s, 4H), 3.65 (s, 4H), 2.76 (s, 3H), 2.12 (ddd, J = 70.1, 45.3, 15.8 Hz, 3H), 1.74 (dd, J = 26.6, 18.6 Hz, 3H), 1.67 – 1.36 (m, 6H), 1.26 (d, J = 8.1 Hz, 3H), 1.13 (dd, J = 10.5, 4.6 Hz, 6H). ^{13}C NMR (101 MHz, DMSO) δ 212.75, 176.97, 155.33, 152.61, 148.93, 148.55, 145.43, 135.33, 134.86, 130.62, 130.29, 128.36, 127.90, 126.97, 126.49, 125.59, 124.64, 124.10, 46.81, 46.31, 45.58, 44.76, 37.39, 33.34, 30.48, 29.50, 25.64, 24.38, 18.89, 18.43, 14.38. Anal. Calcd for $[\text{C}_{49}\text{H}_{51}\text{N}_6\text{ORuS}_2]\text{Cl}$ (940.2298): C, 62.57; H, 5.46; N, 8.93. Found: C, 62.50; H, 5.39; N, 9.02. HRMS (m/z) (ESI) 905.2606 $[\text{C}_{49}\text{H}_{51}\text{N}_6\text{ORuS}_2]^+$.








(6b). Yield 53.2%. ^1H NMR (400 MHz, DMSO) δ 10.57 (s, 2H), 9.82 (d, $J = 5.2$ Hz, 1H), 9.44 – 9.35 (m, 1H), 9.00 (s, 1H), 8.68 (d, $J = 8.4$ Hz, 1H), 8.32 (dd, $J = 8.0, 2.8$ Hz, 1H), 8.03 – 7.90 (m, 2H), 7.82 (s, 1H), 7.47 – 7.35 (m, 2H), 7.29 – 7.21 (m, 1H), 7.18 – 7.09 (m, 2H), 7.02 – 6.83 (m, 4H), 6.76 (s, 2H), 3.37 (s, 8H), 2.86 – 2.67 (m, 3H), 1.29 (d, $J = 8.7$ Hz, 3H), 1.26 (s, 3H), 1.23 (s, 6H), 1.21 (s, 6H), 1.19 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 204.22, 168.66, 155.06, 153.79, 149.47, 135.07, 130.43, 127.78, 127.36, 106.54, 106.08, 100.00, 56.12, 50.44, 41.49, 41.02, 37.40, 33.31, 33.03, 28.27, 27.05, 22.34, 11.76, 10.17, 4.03. Anal. Calcd for $[\text{C}_{49}\text{H}_{53}\text{N}_8\text{ORuS}_2]\text{Cl}$ (970.2516): C, 60.63; H, 5.50; N, 11.54. Found: C, 62.55; H, 5.58; N, 11.46. HRMS (m/z) (ESI) 935.2820 $[\text{C}_{49}\text{H}_{53}\text{N}_8\text{ORuS}_2]^+$.







D:\DATA\UHWHR\20191020\CASE936.29


10/19/19 15:54:11


GASE936.29 #30 RT: 0.10 AV: 1 NL: 1.04E8
T: FTMS + p ESI sid=12.50 Full ms [450.00-1500.00]





(6c). Yield 55.3%. ^1H NMR (400 MHz, CDCl_3) δ 9.53 (d, J = 5.6 Hz, 2H), 8.68 (d, J = 6.0 Hz, 2H), 8.57 (d, J = 8.1 Hz, 2H), 8.08 (s, 2H), 7.80 (s, 2H), 7.66 (ddd, J = 8.9, 4.6, 2.5 Hz, 2H), 7.56 (d, J = 5.3 Hz, 2H), 7.12 (dd, J = 7.4, 5.7 Hz, 3H), 6.97 (s, 1H), 6.87 (d, J = 8.5 Hz, 1H), 4.02 – 3.66 (m, 8H), 2.96 – 2.77 (m, 3H), 1.86 – 1.60 (m, 6H), 1.34 (d, J = 5.3 Hz, 3H), 1.23 (d, J = 3.2 Hz, 6H), 1.19 (d, J = 6.6 Hz, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 214.28, 177.73, 177.69, 158.15, 158.00, 153.71, 153.70, 150.90, 146.76, 146.74, 145.76, 145.74, 136.01, 135.44, 134.91, 127.06, 126.67, 126.00, 24.17, 123.85, 123.84, 123.73, 46.85, 46.83, 46.42, 45.51, 44.93, 37.62, 37.43, 35.76, 33.43, 30.57, 29.70, 5.47, 23.98, 22.19, 18.80, 18.73, 14.14. Anal. Calcd for $[\text{C}_{45}\text{H}_{51}\text{N}_6\text{ORuS}_2]\text{Cl}$ (892.2298): C, 60.55; H, 5.76; N, 9.42. Found: C, 60.62; H, 5.68; N, 9.36. HRMS (m/z) (ESI) 857.2607 $[\text{C}_{45}\text{H}_{51}\text{N}_6\text{ORuS}_2]^+$.





D:\DATA\UHWHR\20191020\2-2se

10/19/19 16:38:00

2-2se #1 RT: 0.01 AV: 1 NL: 4 23E6

T: FTMS + p ESI sid=12.50 Full ms [400.00-1500.00]

